Newron Pharmaceuticals, a biopharmaceutical company developing therapies for patients with neurological diseases, announced the initiation of the short-term explanatory trial with Evenamide to address previously announced potential safety issues raised by the FDA.

Evenamide is a voltage-gated sodium channel blocker, developed by Newron as an add-on therapy for the treatment of schizophrenia. Evanimide (when administered together with some common atypical antipsychotics) has been reported to significantly improve symptoms of psychosis in patients with chronic schizophrenia, in a Phase II study.

The successful completion of the announced explanatory study is a prerequisite for Newron to start its Phase III program. The results are expected by Q3-Q4 2020.

Read more about Newron Pharmaceuticals here.

Image by Colin Behrens from Pixabay